LETTER TO THE EDITOR

10  Fecal microbiota transplant for more than Clostridioides difficile: Dermatology a new frontier

Snyder AM, Abbott J, Jensen MK, Secrest AM
ABOUT COVER
Editorial board member of World Journal of Dermatology, Dr. Zi-Kai Wang, MD, PhD, is an expert in the field of gastrointestinal endoscopy and digestive diseases. He currently serves as Associate Chief Physician in the Department of Gastroenterology and Hepatology of the First Medical Centre, Chinese PLA General Hospital. Dr. Wang’s career research has focused primarily on the human microbiota and its therapeutic benefit for gastrointestinal dysbiosis-related disorders, such as with fecal microbiota transplantation. Moreover, his medical practice focuses on endoscopic therapeutic techniques, including endoscopic retrograde cholangiopancreatography, natural orifice transluminal endoscopic surgery (NOTES), and endoscopic ultrasonography-guided interventional techniques. He is a member of the Gastrointestinal Microbiome Group of the Chinese Society of Gastroenterology, the Beijing Society of Gastroenterology, and the NOTES Group of the Chinese Society of Digestive Endoscopy. (L-Editor: Filipodia)

AIMS AND SCOPE
The primary aim of World Journal of Dermatology (WJD, World J Dermatol) is to provide scholars and readers from various fields of dermatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of dermatology and covering a wide range of topics including acneiform eruptions, acute generalized exanthematous pustulosis, angiolymphoed hyperplasia with eosinophilia, breast diseases, cutaneous fistula, dermatitis, dermatomyositis, erythema, exanthema, facial dermatoses, foot diseases, hair diseases, hand dermatoses, keratoacanthoma, keratosis, leg dermatoses, lipomatosis, lupus erythematosus, mastocytosis, morgellons disease, nail diseases etc.

INDEXING/ABSTRACTING
World Journal of Dermatology is now indexed in China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yan-Xia Xing; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Dermatology

ISSN
ISSN 2218-6190 (online)

LAUNCH DATE
June 2, 2012

FREQUENCY
Irregular

EDITORS-IN-CHIEF
Zekayi Kutlubay

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2218-6190/editorialboard.htm

PUBLICATION DATE
October 25, 2020

COPYRIGHT
© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
LETTER TO THE EDITOR

Fecal microbiota transplant for more than Clostridioides difficile: Dermatology a new frontier

Ashley M Snyder, James Abbott, M Kyle Jensen, Aaron M Secrest

ORCID number: Ashley Morgan Snyder 0000-0002-1980-2092; James Abbott 0000-0002-0952-4148; M Kyle Jensen 0000-0003-3072-0554; Aaron M Secrest 0000-0001-9297-0941.

Author contributions: Snyder AM and Secrest AM coordinated Institutional Review Board approval and data access; Snyder AM, Jensen MK, and Secrest AM provided input in developing methods for the study; Abbott J collected data for this study and addressed the suitability of the data for analysis; Snyder AM drafted the manuscript. All authors were involved in the revision of the manuscript and gave approval for publication.

Conflict-of-interest statement: The authors have no conflicts-of-interest to declare.

Abstract

Fecal microbiota transplant (FMT) has quickly become popular in research not only for recurrent Clostridioides difficile infections but for other chronic conditions as well. Recent, small dermatologic studies have reported improvements in inflammatory skin conditions in individuals treated with FMT, but larger studies are needed to clarify this possible relationship between the skin and the gut microbiome. We conducted a single-center, retrospective chart review to assess changes in acne, dermatitis herpetiformis and/or celiac disease, eczema, and psoriasis. Due to the retrospective nature of this study and the limitations of the current electronic medical record, we were unable to adequately assess cases of these diseases in relation to FMT. However, this study informs us that improvements in retrospective data are needed to formally evaluate this possible association. The better, but more cumbersome, study design would be a prospective, observational study. We encourage others to pursue further interdepartmental research on the influence of the gut microbiome on inflammatory skin diseases.

Key Words: Fecal microbiota transplantation; Skin diseases; Dermatology; Retrospective; Clostridium difficile; Inflammation

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
REFERENCES

1. Rebello D, Wang E, Yen E, Lio PA, Kelly CR. Hair Growth in Two Alopecia Patients after Fecal Microbiota Transplant. *ACG Case Rep J* 2017; 4: e107 [PMID: 28932754 DOI: 10.14309/crj.2017.107]

2. Zamudio-Tiburcio A, Bermúdez-Ruiz H, Reyes-López PA. Psoriasis is candidate for intestinal microbiota therapy.

Core Tip: Future research investigating fecal microbiota transplant’s potential role in treating dermatologic disease needs to focus on large interdisciplinary prospective studies in order to obtain the information needed for determining an association.

Citation: Snyder AM, Abbott J, Jensen MK, Secrest AM. Fecal microbiota transplant for more than *Clostridioides difficile*: Dermatology a new frontier. *World J Dermatol* 2020; 8(2): 10-12
URL: https://www.wjgnet.com/2218-6190/full/v8/i2/10.htm
DOI: https://dx.doi.org/10.5314/wjd.v8.i2.10

TO THE EDITOR

Though we wish this letter could provide more answers than questions, we write to you to acknowledge a failure. Evidence has emerged that fecal microbiota transplant (FMT) can influence skin conditions and their treatments, as demonstrated by reports on alopecia universalis[1], psoriasis[2], acne[3], and melanoma immunotherapy[4]. Further, a case report describing a patient with celiac disease whose clinical symptoms disappeared after FMT[1] led to our curiosity in celiac disease and its skin disease cousin, dermatitis herpetiformis. We were thus inspired to conduct a retrospective chart review on all patients who received FMT at University of Utah (Institutional Review Board #76927) between January 2013 and December 2019. Our aim was to identify individuals diagnosed with inflammatory skin diseases (acne, dermatitis herpetiformis, eczema, and psoriasis) and/or celiac disease (with or without dermatitis herpetiformis) and look for any evidence of these conditions improving or going into remission after FMT. In total, 141 patients were identified as having undergone FMT (based on ICD-10-CM Diagnosis Code Z94.89), though it appeared only 140 went through with FMT based on what we could find in the electronic medical record. Among those who received FMT, most stool samples were administered via colonoscopy. Some patients received more than one FMT in the time frame of interest, though this did not appear to significantly affect dermatologic outcomes. Our sample included pediatric and adult patients, though most were adult. While 141 patients seemed an adequate number to identify patients for a case series, sadly, none of these individuals had consistent dermatologic data to suggest that FMT might alter gut microbiota sufficiently to impact these conditions.

Why should gastroenterologists who administer FMT care about inflammatory skin diseases? The skin microbiome’s role in dermatologic disease has been given much attention, but the gut microbiome is now entering the spotlight in determining skin disease etiology and potential treatments. The studies previously mentioned stir curiosity as to how inflammatory skin diseases might be affected by the gut microbiome and use of FMT. There is much left to discover about the gut microbiome and how it interacts with other organ systems, but we must expand medical research beyond individual departments to further investigate the subject. Further, at our academic medical center, electronic medical records in their current state lack sufficient clinical information regarding pre- and post-FMT skin issues to explore this relationship rigorously. Future research needs to encourage interdepartmental collaboration and preferably should address the subject using a prospective observational study design.

To conclude, we encourage gastroenterologists administering FMT to assess potential effects FMT can have on their patients’ skin diseases, especially inflammatory processes, and we welcome collaboration on a registry or multicenter cohort study for such work. If your patients develop an inflammatory skin disease or their skin disease changes after FMT, please note this in your charting and/or refer your patients to a dermatologist for follow-up. That FMT you administered may have just cured more than a *Clostridioides difficile* infection.
transplantation? EC Microbiol 2019; 15: 455-460

3 Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 2013; 15: 337 [PMID: 23852569 DOI: 10.1007/s11894-013-0337-1]

4 Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechin T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousy AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Poms N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Giltea IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Putreal PA, Daniel CR, Ajani NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison J, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018; 359: 97-103 [PMID: 29097493 DOI: 10.1126/science.aan4236]

5 van Beurden YH, van Gils T, van Gils NA, Kassam Z, Mulder CJ, Aparicio-Pagés N. Serendipity in Refractory Celiac Disease: Full Recovery of Duodenal Villi and Clinical Symptoms after Fecal Microbiota Transfer. J Gastrointestin Liver Dis 2016; 25: 385-388 [PMID: 27689204 DOI: 10.15403/jgld.2014.1121.253.cel]
